Sophie C Joosten
Overview
Explore the profile of Sophie C Joosten including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
496
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joosten S, Smits K, Aarts M, Melotte V, Koch A, Tjan-Heijnen V, et al.
Nat Rev Urol
. 2018 Jun;
15(7):430-451.
PMID: 29867106
Renal cell carcinoma (RCC) is characterized by an infrequent number of somatic mutations. By contrast, epigenetic aberrations are commonly found in RCC, indicating that epigenetic reprogramming is an important event...
2.
Koch A, Joosten S, Feng Z, de Ruijter T, Draht M, Melotte V, et al.
Nat Rev Clin Oncol
. 2018 May;
15(7):467.
PMID: 29713045
The originally published article contained an error in the acknowledgements section in which the Universiteitsfonds Limburg/SWOL is incorrectly presented as awarding an SU2C- DCS International Translational Cancer Research Dream Team...
3.
Koch A, Joosten S, Feng Z, de Ruijter T, Draht M, Melotte V, et al.
Nat Rev Clin Oncol
. 2018 Apr;
15(7):459-466.
PMID: 29666440
Changes in DNA methylation in cancer have been heralded as promising targets for the development of powerful diagnostic, prognostic, and predictive biomarkers. Despite the existence of more than 14,000 scientific...
4.
Joosten S, Deckers I, Aarts M, Hoeben A, van Roermund J, Smits K, et al.
Epigenomics
. 2017 Aug;
9(9):1243-1257.
PMID: 28803494
Aim: Despite numerous published prognostic methylation markers for renal cell carcinoma (RCC), none of these have yet changed patient management. Our aim is to systematically review and evaluate the literature...
5.
van Vlodrop I, Joosten S, De Meyer T, Smits K, Van Neste L, Melotte V, et al.
Clin Cancer Res
. 2016 Nov;
23(8):2006-2018.
PMID: 27756787
The currently used prognostic models for patients with nonmetastatic clear cell renal cell carcinoma (ccRCC) are based on clinicopathologic features and might be improved by adding molecular markers. Epigenetic alterations...